In a subset of patients with high-risk prostate cancer, the combination of abiraterone acetate plus prednisone (AAP) and apalutamide may improve outcomes when added to salvage radiation therapy.
15.02.2023 - Veracyte, Inc. (Nasdaq: VCYT) today announced that data published in the International Journal of Radiation Oncology, Biology, Physics (aka, “The Red Journal”) demonstrate that the company’s Decipher Prostate Genomic Classifier can improve risk . Seite 1